CN107753645A - Treat rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases and preparation method thereof - Google Patents

Treat rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases and preparation method thereof Download PDF

Info

Publication number
CN107753645A
CN107753645A CN201711198150.8A CN201711198150A CN107753645A CN 107753645 A CN107753645 A CN 107753645A CN 201711198150 A CN201711198150 A CN 201711198150A CN 107753645 A CN107753645 A CN 107753645A
Authority
CN
China
Prior art keywords
parts
rutin
oral liquid
cardiovascular
chinese medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711198150.8A
Other languages
Chinese (zh)
Inventor
付平国
刘文瑞
欧玉莲
王建买
付嫦娥
刘小军
欧召国
付玉香
李凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hengyang Huashengda Forestry Science And Technology Co Ltd
Original Assignee
Hengyang Huashengda Forestry Science And Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hengyang Huashengda Forestry Science And Technology Co Ltd filed Critical Hengyang Huashengda Forestry Science And Technology Co Ltd
Priority to CN201711198150.8A priority Critical patent/CN107753645A/en
Publication of CN107753645A publication Critical patent/CN107753645A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/08—Mineral waters; Sea water
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A61K36/195—Strobilanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315—Isatis, e.g. Dyer's woad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides a kind of rutin traditional Chinese medicine oral liquid for treating cardiovascular and cerebrovascular diseases, in terms of weight fraction, including the following raw material：100 parts of rutin, 0.5 2 parts of chlorogenic acid, 0.05 0.10 parts of isatis root extract, 1,000 2000 parts of mineral water, 0.2 0.8 parts of yeast zinc, 0.05 0.10 parts of radix glehniae, 0.001 0.005 parts of yeast chromium, 0.03 0.10 parts of Co-Q10,13 parts of Honegsukle flower P.E, 5 10 parts of Calyx Seu Fructus Physalis extract.The rutin oral liquid is adapted to：Hypertension, high fat of blood and insomniac, cardiac etc..

Description

Treat rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases and preparation method thereof
Technical field
The invention belongs to technical field of traditional Chinese medicines, and in particular to a kind of rutin traditional Chinese medicine oral liquid for treating cardiovascular and cerebrovascular diseases and its Preparation method.
Background technology
Nowadays, cardiovascular and cerebrovascular disease turns into one of three big killers for threatening health of people, due to the side effect ratio of Western medicine It is larger, therefore raising with long-term treatment, Chinese medicine preparation often turns into first choice；Wherein using refined rutin as raw material medicine very Welcome by patient；According to statistics, current China town and country cardiovascular and cerebrovascular diseases occur as 1.2%~1.8%, and the death rate is one thousandth, For national cardiovascular disease number of the infected in 1,600,000 people or so, the occurrence cause of cardiovascular and cerebrovascular diseases is mainly hypertension, high fat of blood； Rise 54% between 1979~1991,12 years, the age is bigger, the easier generation of cardiovascular and cerebrovascular disease, now I For more than 60 years old old man of state more than 1.3 hundred million, China has been enter into aging society；Predicted according to the World Health Organization, 2020 complete The ball population of more than 40~60 years old will rise to doctor's on October 13rd, more than 1,200,000,000,1997 from current 7.4 hundred million Economic report and the World Health Organization are learned on 2 17th, 1997 numerals announced in Geneva；1994 in whole death There is 40% to die from cardiovascular and cerebrovascular disease in number.
Rutin product has softening cardiovascular and cerebrovascular, decompression, lipid-loweringing, pre- anti-stroke, and norcholesterol, cholagogic are convenient, promote new The functions such as old metabolism, and capillary toughness can be strengthened, improve cerebrovascular function, it is evident in efficacy for treating hypertension, it is domestic Outer demand is very big；It is medicine-food two-purpose medicinal material as defined in the Ministry of Public Health, develops health food and functional food at home and abroad all has There is wide market, supply falls short of demand always for its high-end product, possesses great development space.
The content of the invention
An object of the present invention is to provide a kind of rutin traditional Chinese medicine oral liquid for treating cardiovascular and cerebrovascular diseases, and the rutin is oral Liquid energy enough treats a variety of cardiovascular and cerebrovascular diseases.
The second object of the present invention is the preparation method for providing above-mentioned rutin oral liquid.
The rutin traditional Chinese medicine oral liquid of present invention treatment cardiovascular and cerebrovascular diseases, in terms of weight fraction, including the following raw material：Rutin 100 parts, chlorogenic acid 0.5-2 parts, isatis root extract 0.05-0.10 parts, yeast zinc 0.2-0.8 parts, radix glehniae 0.05-0.10 Part, yeast chromium 0.001-0.0005 parts, Co-Q10 0.03-0.10 parts, Honegsukle flower P.E 1-3 parts, Calyx Seu Fructus Physalis extract 5- 10 parts, mineral water 1000-2000 parts.
Preferably, mineral water is Zhangjiajie mineral water.
Preferably, bauhinia leaf extract can also be added in the rutin traditional Chinese medicine oral liquid of present invention treatment cardiovascular and cerebrovascular diseases 0.1-1 parts.
Preferably, carthamin 0.5-1.0 can also be added in the rutin traditional Chinese medicine oral liquid of present invention treatment cardiovascular and cerebrovascular diseases Part.
Preferably, root of red-rooted salvia phenolic acid 0.005- can also be added in the rutin traditional Chinese medicine oral liquid of present invention treatment cardiovascular and cerebrovascular diseases 0.009 part, preferably root of red-rooted salvia phenolic acid B.
Preferably, Fructus lycii P.E can also be added in the rutin traditional Chinese medicine oral liquid of present invention treatment cardiovascular and cerebrovascular diseases 0.001-0.005 parts and notoginseng total saponin 0.5-1.5 parts.
Preferably, tangshenoside 0.005- can also be added in the rutin traditional Chinese medicine oral liquid of present invention treatment cardiovascular and cerebrovascular diseases 0.009 part.
Preferably, panaquilon 0.005- can also be added in the rutin traditional Chinese medicine oral liquid of present invention treatment cardiovascular and cerebrovascular diseases 0.01 part, GL-B 0.005-0.009 parts.
The preparation method of the rutin traditional Chinese medicine oral liquid of present invention treatment cardiovascular and cerebrovascular diseases, in turn includes the following steps：
（1）Raw material is weighed up in proportion, is put into defined container；
（2）Raw material in addition to mineral water is mixed；Stirring 45-60 minutes produce rutin oral liquid in addition mineral water.
Rutin oral liquid of the present invention is precipitated as normal phenomenon, using it is front upper and lower rock corkage it is ready-to-drink；Usage and dosage:Mouthful Clothes, a 10-20ml, 3 times a day.
Embodiment
Embodiment of the present invention is described in detail below in conjunction with example, but those skilled in the art will manage Solution, the following example is merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.
Mineral water is Zhangjiajie mineral water in embodiment.
Embodiment 1
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1580g yeast zinc 0.5g radix glehniaes 0.08g
Yeast chromium 0.003g Co-Q10 0.04g Honegsukle flower P.Es 1.9g
Calyx Seu Fructus Physalis extract 6g.
Embodiment 2
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1580g yeast zinc 0.5g radix glehniaes 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Co-Q10s 0.04g
6 parts of Honegsukle flower P.E 1.9097g Calyx Seu Fructus Physalis extracts.
Embodiment 3
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1570g yeast zinc 0.5g radix glehniaes 0.08g
Yeast chromium 0.003g carthamin 0.8g Co-Q10s 0.04g
Honegsukle flower P.E 1.9097g Calyx Seu Fructus Physalis extracts 6g.
Embodiment 4
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1600g yeast zinc 0.5g radix glehniaes 0.08g
Yeast chromium 0.003g Co-Q10 0.04g Honegsukle flower P.Es 1.9g
Root of red-rooted salvia phenolic acid 7mg Calyx Seu Fructus Physalis extracts 6g.
Embodiment 5
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1600g yeast zinc 0.5g radix glehniaes 0.08g
Yeast chromium 0.003g carthamin 0.8g Co-Q10s 0.04g
Honegsukle flower P.E 1.9g root of red-rooted salvia phenolic acid B 7mg Calyx Seu Fructus Physalis extracts 6g.
Embodiment 6
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1500g yeast zinc 0.5g radix glehniaes 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Co-Q10s 0.04g
Honegsukle flower P.E 1.9g Calyx Seu Fructus Physalis extract 6g Fructus lycii P.Es 3mg
Notoginseng total saponin 1g.
Embodiment 7
Rutin 100g chlorogenic acid 1.5g isatis root extracts 0.09g
Mineral water 1400g yeast zinc 0.3g radix glehniaes 0.06g
Yeast chromium 0.004g bauhinia leaf extract 0.7g Co-Q10s 0.05g
Honegsukle flower P.E 1.9g Calyx Seu Fructus Physalis extract 6g Fructus lycii P.Es 4mg
Notoginseng total saponin 0.9g.
Embodiment 8
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1380g yeast zinc 0.5g radix glehniaes 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Co-Q10s 0.04g
Honegsukle flower P.E 1.9g Calyx Seu Fructus Physalis extract 6g tangshenoside 7mg
Panaquilon's 7mg GL-Bs 6mg.
Embodiment 9
Rutin 100g chlorogenic acid 1.1g isatis root extracts 0.05g
Mineral water 1500g yeast zinc 0.5g radix glehniaes 0.08g
Yeast chromium 0.004g bauhinia leaf extract 0.7g Co-Q10s 0.05g
Honegsukle flower P.E 1.8g Calyx Seu Fructus Physalis extract 7g tangshenoside 9mg
Panaquilon's 6mg GL-Bs 5mg.
Embodiment 10
Rutin 100g chlorogenic acid 1g isatis root extracts 0.07g
Mineral water 1300g yeast zinc 0.5g radix glehniaes 0.08g
Yeast chromium 0.003g bauhinia leaf extract 0.5g Co-Q10s 0.04g
Honegsukle flower P.E 1.9g Calyx Seu Fructus Physalis extract 8g root of red-rooted salvia phenolic acid B 8mg tangshenoside 7mg
Fructus lycii P.E 6mg notoginseng total saponins 7mg.
Embodiment 11
Rutin 100g chlorogenic acid 1.2g isatis root extracts 0.07g
Mineral water 1600g yeast zinc 0.5g radix glehniaes 0.08g
Yeast chromium 0.005g bauhinia leaf extract 0.4g Co-Q10s 0.03g
Honegsukle flower P.E 1.7g Calyx Seu Fructus Physalis extract 5g root of red-rooted salvia phenolic acid B 6mg tangshenoside 6mg
Fructus lycii P.E 8mg notoginseng total saponins 7mg.
The preparation method of the rutin oral liquid of above example comprises the following steps：
（1）Raw material is weighed up in proportion, is put into defined container；
（2）Raw material in addition to mineral water is mixed；Add in mineral water to stir 60 minutes and produce rutin oral liquid.
Rutin oral liquid clinical effectiveness of the embodiment of the present invention is as follows：
Experimental method：
A groups:Hypertensive patient 110, it is divided into 11 groups, every group of 10 people, every group of patient takes embodiment 1-11 rutin mouth respectively Liquid is taken, 3 times a day, each 10mL, 40 minutes warm boiled waters before meals, 30 days are 1 course for the treatment of, take 3 courses for the treatment of.
B groups：Thrombolysis contrasts, and patient 120 is divided into 12 groups, every group of 10 people, and every group of rutin for taking embodiment 1-11 respectively is oral Liquid, western drug treatment（Control group）, 3 times a day, each 20mL, 40 minutes warm boiled waters before meals 30 days are 1 course for the treatment of, two Group patient is in age, sex, thrombosis position, the course of disease, clinical manifestation etc. comparing difference without conspicuousness.
Experimental result：
A groups:The preceding patient's diastolic pressure of medication is more than 180mmHg, and systolic pressure is more than 110mmHg, main suit's giddy, tinnitus, uncomfortable in chest, gas Short, insomnia, head Doppler show that blood vessel has Partial Blocking；After taking 5 courses for the treatment of, blood pressure tends to be steady, and lives and recovers completely.
That takes hypertensive patient after 3 courses for the treatment of the results are shown in Table 1.
The hypertensive patient of table 1 takes the therapeutic effect of rutin oral liquid
。
B groups：The evaluated order of severity of thrombosis patients is suitable before medication, and patient is in age, sex, thrombosis position, disease Journey, clinical manifestation etc. comparing difference are without conspicuousness；Medicine of the present invention, without complication, has no haemorrhage during thrombolysis Shape, occasionally there is patient slight gastrointestinal reaction occur, disappeared after giving anti symptom treatment.
The experimental result of thrombosis patients is shown in Table 2 after taking 40 days.
Table 2
。
As can be seen from Table 5, rutin oral liquid treatment group is evident in efficacy is higher than western medicine group, and rutin oral liquid thrombolysis is A kind of safely and effectively method.
Above content describes the general principle and principal character of the present invention, and the present invention is not limited to the above embodiments, not On the premise of departing from spirit and scope of the invention, various changes and modifications of the present invention are possible, and these changes and improvements are both fallen within In scope of the claimed invention.

Claims (10)

1. a kind of rutin traditional Chinese medicine oral liquid for treating cardiovascular and cerebrovascular diseases, in terms of parts by weight, including the following raw material：100 parts of rutin, Chlorogenic acid 0.5-2 parts, isatis root extract 0.05-0.10 parts, yeast zinc 0.2-0.8 parts, radix glehniae 0.05-0.10 parts, yeast Chromium 0.001-0.005 parts, Co-Q10 0.03-0.10 parts, Honegsukle flower P.E 1-3 parts, Calyx Seu Fructus Physalis extract 5-10 parts, mineral spring Water 1000-2000 parts.
2. the rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases is treated according to claim 1, it is characterised in that described rutin is Mineral water is Zhangjiajie mineral water.
3. the rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases is treated according to claim 1, it is characterised in that can also add purple Chaste tree leaf extract 0.1-1 parts.
4. the rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases is treated according to claim 1, it is characterised in that can also add red Flower glucoside 0.5-1.0 parts.
5. according to the rutin traditional Chinese medicine oral liquid of the treatment cardiovascular and cerebrovascular diseases of claim 1 or 4, it is characterised in that can also add Root of red-rooted salvia phenolic acid 0.005-0.009 parts.
6. the rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases is treated according to claim 1, it is characterised in that described danshensu Acid is root of red-rooted salvia phenolic acid B.
7. the rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases is treated according to claim 1, it is characterised in that can also add Chinese holly Matrimony vine extract 0.001-0.005 parts and notoginseng total saponin 0.5-1.5 parts.
8. the rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases is treated according to claim 1, it is characterised in that can also add party Join glucoside 0.005-0.009 parts.
9. the rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases is treated according to claim 1, it is characterised in that can also add people Join glucoside 0.005-0.01 parts, GL-B 0.005-0.009 parts.
10. the preparation method of the rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases is treated according to claim 1, it is characterised in that according to It is secondary to comprise the following steps：
（1）Raw material is weighed up in proportion, is put into defined container；
（2）Raw material in addition to mineral water is mixed；Stirring 45-60 minutes produce rutin oral liquid in addition mineral water.
CN201711198150.8A 2017-11-25 2017-11-25 Treat rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases and preparation method thereof Pending CN107753645A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711198150.8A CN107753645A (en) 2017-11-25 2017-11-25 Treat rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711198150.8A CN107753645A (en) 2017-11-25 2017-11-25 Treat rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases and preparation method thereof

Publications (1)

Publication Number Publication Date
CN107753645A true CN107753645A (en) 2018-03-06

Family

ID=61275348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711198150.8A Pending CN107753645A (en) 2017-11-25 2017-11-25 Treat rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases and preparation method thereof

Country Status (1)

Country Link
CN (1) CN107753645A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1931269A (en) * 2006-10-13 2007-03-21 深圳市生物谷科技有限公司 Rutin containing medicine composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1931269A (en) * 2006-10-13 2007-03-21 深圳市生物谷科技有限公司 Rutin containing medicine composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
田洋: "槐米中芦丁的提取工艺研究进展", 《广州化工》 *

Similar Documents

Publication Publication Date Title
CN104383132B (en) Traditional Chinese medicine preparation used for treating gastric ulcer and preparation method
CN103211930B (en) Traditional Chinese preparation for reducing blood fat and blood pressure
CN103251814A (en) Traditional Chinese medicine preparation for adjusting hypertension, hyperlipemia and hyperglycemia
CN101467673A (en) Compound ginseng health product and preparation method thereof
CN104147345B (en) A kind of Chinese medicine composition for treating cardiovascular autonomic neuropathy
CN103463494A (en) Chinese herbal preparation for treating hypertention
CN107661409A (en) A kind of rutin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof
CN107753645A (en) Treat rutin traditional Chinese medicine oral liquid of cardiovascular and cerebrovascular diseases and preparation method thereof
CN105726931A (en) Traditional Chinese medicine preparation for treating chronic heart failure and preparation method thereof
CN103584095A (en) Health-care drink for treating hypertention and preparation method of health-care drink
CN102949571A (en) Medicine for treating chronic osteomyelitis
CN103013806A (en) Health-care therapeutic herbal vinegar
CN107854567A (en) A kind of Quercetin traditional Chinese medicine oral liquid and preparation method thereof
CN102274357B (en) Pharmaceutical composition for treating coronary arteriosclerotic heart disease and preparation method thereof
CN102988747B (en) Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof
CN108079119A (en) Treat rutin oral liquid of cardiovascular and cerebrovascular disease and preparation method thereof
CN102293296B (en) Blood-pressure-reducing anticancer tea
CN104522493A (en) Health porridge for treating coronary atherosclerosis and preparation method of health porridge
CN104740518A (en) Traditional Chinese medicine used for treating gallstones
CN104740499A (en) Traditional Chinese medicine oral decoction for treating lung cancer
CN104127670A (en) Traditional Chinese medicine decoction for treating arrhythmia
CN104116908A (en) A traditional Chinese medicine decoction for treating arrhythmia
CN102716293A (en) Capsule for treating hypertension, hyperlipemia, arteriosclerosis and coronary heart disease
CN102824599B (en) Traditional Chinese medicine tincture for treating various skin eruptions caused by diabetes
CN108042599A (en) A kind of Quercetin oral liquid for treating cardiovascular and cerebrovascular disease and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180306